-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 CzULE80DoAeWPBCIREnmGIioctAjjWCtvGb8uXuzdk1ZsPlHBPRa8f2PDVjJLl2f
 mv1FwMJwEubgbCiH6hp8zg==

<SEC-DOCUMENT>0001193125-10-004017.txt : 20100111
<SEC-HEADER>0001193125-10-004017.hdr.sgml : 20100111
<ACCEPTANCE-DATETIME>20100111093758
ACCESSION NUMBER:		0001193125-10-004017
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20100111
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20100111
DATE AS OF CHANGE:		20100111

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARCA biopharma, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22873
		FILM NUMBER:		10519207

	BUSINESS ADDRESS:	
		STREET 1:		8001 ARISTA PLACE
		STREET 2:		SUITE 200
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021
		BUSINESS PHONE:		720-940-2200

	MAIL ADDRESS:	
		STREET 1:		8001 ARISTA PLACE
		STREET 2:		SUITE 200
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:3px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P
STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>WASHINGTON, D.C. 20549 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P
STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K </B>
</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P
STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman"
SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d) of the </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Securities Exchange Act of 1934 </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Date of Report (Date of Earliest Event Reported): January&nbsp;11, 2010 </B></FONT></P> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px"
ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>ARCA biopharma, Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact Name of Registrant as
Specified in Charter) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>000-22873</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>36-3855489</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or Other Jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"
ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>of Incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission File Number)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(I.R.S. Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>8001 Arista Place, Suite 200, Broomfield, CO 80021 </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of Principal Executive Offices) (Zip Code) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(720) 940-2200 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Registrant&#146;s Telephone Number, Including Area Code)
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Not Applicable </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>(Former Name or Former Address, if Changed Since Last Report) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P
STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check the
appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE> <P
STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:3px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P
STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;8.01</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Other Events </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>On
January&nbsp;11, 2010, ARCA biopharma, Inc. issued a press release announcing that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for its U.S. Patent Application Number 11/226,908 entitled &#147;Methods for Treatment
with Bucindolol Based on Genetic Targeting.&#148; The press release is attached as Exhibit&nbsp;99.1 hereto, the contents of which are incorporated herein by reference. <B> </B></FONT></P> <P
STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Financial Statements and Exhibits </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman"
SIZE="2">(d) Exhibits </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:25pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:39pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release titled &#147;ARCA biopharma receives Notice of Allowance for patent for treating heart failure patients with bucindolol based on genetic testing&#148;, dated January
11, 2010.</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated: January&nbsp;11, 2010 </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARCA biopharma, Inc.</B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>(Registrant)<B></B></FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/&nbsp;&nbsp;&nbsp;&nbsp;M<SMALL>ICHAEL</SMALL> R.
B<SMALL>RISTOW&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</SMALL></FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name:</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Michael R. Bristow</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Title:</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>President and Chief Executive Officer</B></FONT></TD></TR>
</TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT INDEX </B></FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:25pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:39pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release titled &#147;ARCA biopharma receives Notice of Allowance for patent for treating heart failure patients with bucindolol based on genetic testing&#148;, dated January
11, 2010.</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="right">

<IMG SRC="g44365g07n98.jpg" ALT="LOGO"> </P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Contact: </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman"
SIZE="2">Derek Cole </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vice President, Investor Relations&nbsp;&amp; Corporate Communications </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">720.940.2163 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>derek.cole@arcabiopharma.com </U>
</FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARCA BIOPHARMA RECEIVES NOTICE OF ALLOWANCE FOR PATENT FOR </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"
ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>TREATING HEART FAILURE PATIENTS WITH BUCINDOLOL BASED ON </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman"
SIZE="2"><B>GENETIC TESTING </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Broomfield, CO, January&nbsp;11, 2010</I> &#150; ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical
company developing genetically targeted therapies for heart failure and other cardiovascular diseases, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its U.S. Patent Application
Number 11/226,908 entitled &#147;Methods for Treatment with Bucindolol Based on Genetic Targeting.&#148; The Notice of Allowance is the USPTO&#146;s official communication that the examination of the patent application has been successfully
completed and that a patent will be issued. Once issued, the patent will provide coverage for methods of treating heart failure patients with bucindolol based on genetic testing. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#147;We are very pleased with the USPTO&#146;s decision to grant this patent which extends our pharmacogenetic intellectual property protection around bucindolol in to 2025,&#148; said Michael R.
Bristow, President and Chief Executive Officer of ARCA. &#147;This allowance and anticipated issuance of the patent highlight ARCA&#146;s belief in, and commitment to, developing genetically targeted therapies for the treatment of heart failure and
other cardiovascular disease.&#148; </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px;padding-bottom:3px;"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About Gencaro<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:3px;"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Gencaro</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2">
(bucindolol hydrochloride) is a pharmacologically unique beta-blocker and mild vasodilator being developed for the treatment of chronic heart failure (HF). Gencaro is an oral tablet formulation, dosed twice daily. Gencaro is considered part of the
beta-blocker class because of its property of blocking beta-1 as well as beta-2 receptors in the heart, preventing these receptors from binding with other molecules that would otherwise activate the receptor. Because of its mild vasodilator effects,
the Company believes Gencaro is well-tolerated in patients with advanced HF. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About ARCA biopharma </B></FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:3px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARCA biopharma is dedicated to developing genetically-targeted therapies for heart failure and other cardiovascular diseases. The
Company&#146;s lead product candidate, Gencaro</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2">
(bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for heart failure. ARCA has identified common genetic variations that it believes predict individual patient response to
Gencaro, giving it the potential to be the first genetically-targeted heart failure treatment. ARCA is collaborating with Laboratory Corporation of America to develop the companion genetic test for Gencaro. For more information please visit
<U>www.arcabiopharma.com</U>. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Safe Harbor Statement </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">This press release contains &#147;forward-looking statements&#148; for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements include, but are not
limited to, statements regarding the issuance of, and protection provided by, U.S. Patent Application Number 11/226,908 entitled &#147;Methods for Treatment with Bucindolol Based on Genetic Targeting.&#148; Such statements are based on
management&#146;s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the
risks and uncertainties associated with: the Company&#146;s financial resources and whether they will be sufficient to meet the Company&#146;s business objectives and operational requirements; the protection and market exclusivity provided by the
Company&#146;s intellectual property; risks related to the drug discovery and the regulatory approval process; and, the impact of competitive products and technological changes. These and other factors are identified and described in more detail in
ARCA&#146;s filings with the SEC, including without limitation the Company&#146;s annual report on Form 10-K for the year ended December&nbsp;31, 2008, the Company&#146;s quarterly report on Form 10-Q for the quarter ended September&nbsp;30, 2009
and subsequent filings. The Company disclaims any intent or obligation to update these forward-looking statements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">###
</FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g44365g07n98.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g44365g07n98.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`4`#@`P$1``(1`0,1`?_$`,H````%!0$`````````
M```````'"`D*`0(#!`8%`0$``00#`0$`````````````!P$#!0@"!@D$"A``
M`00!`@0#!`4)`PD)`````0(#!`4&$0<`(1((,1,)05$B%&&1,A46@;%"4G(C
M)!<*\'$SP6+4)7:6ME<YH=&"0U-$-2<9$0`!`P,"`P,'!@@+"0`````!``(#
M$00%(3$2!@=!41-A<8$B,A0)D:&Q,Q4(\,'1X=)SLQ9"4F*2DR0T5%4V%X*B
M(U-C1*1V-__:``P#`0`"$0,1`#\`GQW%U74$"7:V\N+75D%A<J9/FR&XT6+'
M:!4XZ^\Z4H0E('OU).@XQV6S&+P6/DRF8GCM["%I<][W!H:T"M=2%<B@N;E[
M8;.-TMPXT#1ND-9?Z@NV=-.=@XGC60YLAE:T*L6G8]'6/=!*2J&[.;?ER$E0
MY*+"$D<P3QH5SY\1'I;RMEGXOENRN,X(W%IDBF9"SB&X!=&\'SU4IXCI-FLC
M;B>\E;:DBO"6.<?30BBY5'J)5[G24[/7Q0L`I7^*:[0^\?\`Q/Z)Y<=*9\2K
M$R1F1G)M^:;#W^'7_P`=9%G1RY?+X7O\0/ZIWZ:WU>H'#2RAY6T5T$N>;T#\
M55Y4HM*"2`/NCQU/Y.+@^)'C_`;<GDO(")S7&OO\.A;0$?V??57F=&977)M_
MM.$$"M?"=^FO-<]16L:2%.[07B-5E!2<JKNH%.G7TC[H^+H!''SP_$MQ$H!/
M)M^TN8UP_K\.QK7_`+?L_&KD?12>5C7,R41+B13PG=G^VCJVM[T-JMRK"+1R
M$V&'7TU:6H47("R*Z>\5)26(=PS_``QD:J&B'DLJ4>0'$]=*/OL=)>I=PW&W
MDGV1FWO:QL$TK9"7.-`.(!@WTV74.8^FN?P%7M'O%N!4N:TC0;FAKMYTK)$H
M+U_=D:>/Q#QUT(&H!.GO\/=QN&'AQXFT,!8'!PU!K7:GDU]*CLU#^`"I&ZR>
M>/U3]?%0015NH5=#MJ$//'ZI^L<514+Y!_P_AT!ZNM(T^UU:I^URT&GL.OLT
MX(M:)9Q9S3<F&ZS+BO(\QF5%D-2H[J->DJ;?84XRM'5J`0HZE*O=P1;7GC]4
M_6."*AD`?HJ/@!H"KF>0Y)2H^/T<$5P=421Y3@T)2"1H#T\B1KH>DGP/MX(J
M><K73R7-=?8#H?\`Q:!(_*1P15\W0:K;6@>&JNGQ]@Y$^/!%3SQ[4*!]QT!'
M]^A(X(AYX_5/UC@B'GC]4_6."+&[,889<DOK;8C-`EU]]UIEII(\5.+=6E"$
M@'Q)'!%SK6=X8^^8S.6XL\^"`&&LCIW'^>FG4RB65IU/AX\$70MS$/(#C*?.
M;4-4NL+0^TH?YJVBKJY^X'@BO1)"DA700%`*'/GH4@\^0T()T_)P17>>/U3]
M8X(J?,`DA*%*4`3H--/#D-3H.I7LX(M>-9Q)K+<B&\Q+C.]?ER(DAF2PLMJ*
M'0'F%N-$MNI*3HH_$"/$<$6SYX_5/UC@BO0X%G0`CEK^;_OX(FO_`%"<^MFI
M^'[:0W'6ZB75KRN]:;/2+!2+%VOJHCH((>::7'?=*/`J"20>7'E;\17J;EK&
MYQW2O&<4<-Y9-NYI&NHXL=/)%P4!J12(]G:5-O2?"MECDSGJF5DWA@'L]5KJ
M^GB^9(0PS!)%[(2F,P')J$ZM1B$HD260.LB.4!:7G1I]G74CV:\>;/)_(%QS
M3=/L;9CHK6,58TM/'*10DBOK'M.G<IIR6;EQK"RXX2QX]H>RWMU(T&U-:;I3
MF([4-6U+9!$9;DZE0FS^7``=<KB[Y%BR/<_7O=+B@>?1J.-P.1>AMKDL'-,]
MI-Y:LJYE/7`':6^T!WDBBCB]YM=#*)6?4DT#NP^8[+L[':-2L>PY<2$I]^R7
M=,-("$]3KWWG':82?AZ@IU"M![=.?LX[[<]#L>_DK"R0QAT^0O)AZHJ>$NJ-
M!73N6,CYM<[)O<YX'J:Z@>C\O<BMS;:<M6AHZN.J4]!_@5="`XN7,:07+%UL
MZA#;#;R5`.%02EM`)U)UXA;J!T6./S'V=BZ`VL0#G?P0=06N.P(IL35=@Q',
MLWA->ZNKJCR[)+N28ZNHF/);<0\II2DK6P=$A:-#HT\.E14DCX5:\CS'&I6=
MPEQRYEGOQX\++L-6R5+07C8M)(!-=J*3;*YFS$/ASE@@<*&M!H=]T]7VCY]8
M[A;+45A<O/2[6BF3L7F37EJ>?G(JG4F#(?<5JMQU<!]H*)YDCGSX]]/N>=2[
M_J1T0LLGE2Y]_:2NMI#N26!IU\M'#T46IG4#%P<O\PS1P@<$GK-`\M1IZ=4I
MT#3E_;GSXVD!:X59HU=$A:6Q@.WU^<DH<55U-H>K/W3.=JO9GN)?T$SR-R]R
M63M/MBPT"J>F_P`LBR&K2[AM-!4EQ.+XTW,FDH'P+;3KXC@B0S_3Q=S'\Q^V
MK,.W2]LG)>2[!9"J=CC<R0I^8_MOG,B19PE(<<6IQ]JGR,3&">00AUL>!3P1
M2%>"+S[:LC7=594LT.JA7$"753DL2)$-]4*P8<B2TL38;K$N$^6'5=#S2TN-
M*T4DA0'!%&5]5WL@B=HG;E/[C.V7N`[HL`F8WEN)U%YA<ON"W'R+&[BKR>R%
M09-?(O[Y^ZI[2M>+:D#YA;3J24E*?$D2>_1Y[:LA[_,?WCW`[C.YSNGNJ;;_
M`";'<1H\1QW?7/<=9G2K.D<NI]I<VK5L]/=;0"A#3+2FTC0DJ)X(G,^Y#TIK
MG`=M<KW`[)^Z'NNVIWAPZBLLDIJ:TWVSC-<2S1=-&5/<QF=%R";,F5TJS8CN
M(CR$..-I?4D.,K3KH1)W]';U<MSNX3<1CM6[HI<._P`^LJFSG[9;F(@PZ>WO
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M<<;SW$96;8G8;@9,K(-LV_Q16.1_O%ZOG0X648'8%/RKLAYAM^,IQ*9`=0KJ
M!%,&J;&/<5=;;PR%0[:!#M(:DE)28EA&:EQBDI/24EEX<QXG7@B]#@B0/ZEW
M="KM)[0]S=RZJ0$YY<P/Y=[60F^M4J9N#FK,BNJ)#+314ZM-%"1*LED)40F)
M[O$B:K_ITNYM>8[0[H]KV3VSEAD6U5__`#'PUZ;(<>F6&%Y])D'(&D*D*+C@
MI<Q:<=6-24BR3X`:<$4DS@BS,?;/[)_..")I?ORBHD[VX6'6TNM#;Z("C53:
MM?Q%?:Z.IU4D:?1QXN?$4;X_7C!VTA_J[N6XJANC_P"VW>Q[O2MB^DS:<IW4
MG:+QW[.-:.U>&4U@(B8EPFFLDEGR&[-+K3/FE:5-%NV80XVPYU_9#B&SKIJ3
MPZ-<AX(Q07^,O_=LR/JQ/5P+B*4U:X4/L^E?)S#E[L.?;R-+[8^T!W#7\25Q
M:WE9MT_C\RXJ6G-PI[4UD0*V5%177E<XV8JKJT\AMWR4.D!)+8"G5C73Q/&Z
M>:S."Z916$^>LA^^UW!P\$/U<S"-WAKJ4(`K6BCZWAN\W)-#"2W&QZM)[#O0
M?GV7<XK*M[&)73%X]2B-3AYZN981*2Y7*E`K?7%<=?=\QTE6H*P="..^<F9C
M*9W&Q7DV-M665H.)C&M`,37?Q=?::--RL??6L5LP.<XF9P'%KN1NN/RO#&GJ
M!T8XJ'7UMD%KR3([FQ1'G.O^:HKJNM*')#304-74-)_?!0&HXZOS;R38MP4M
MSRJ(1BKI[WSSW%"][S3U6<52`RIKH*\0W7WV69N3*P.)-/9:-J=_G\^W8F\]
MT<8I81?3#??M%H)(DMQ37UR%$J"T1T2`N3(#)Y@]"`1QYC]:.3L!8N?<6\@G
MNF5=45HTC6NP4S\OY6XEC9&_9Q`^5+@["F_*V:M$::`9U=Z?W&%6<;^_#G_^
M%7?_`+!/^QM5$/5W_,D/ZL?24MOC?1GL^D_25'+MU0D@:A)5S`T'B=3H-/I)
MXYJB9-4U5]]?JHY/66D5K(>WWT^=OK?#Y4.0A,FAR/N)WAK)-1?!Y*TEI^7A
M^)K?8"/B\J0UU<B1J1,&]H&16OIC^KC8;4Y5/D5^#G<*]V)R25,=6U'E;>9_
M*B3MN,LD'X6W6XTB9524+4-4H+@'Z0X(ITB3\('+X>I/PJ*@.E1`^(\SJ.?!
M%7@B9S]>/_IN[F_[=;4_\:UO!$C?^FL'1L9W.%1T_P#N3%0.1&I.%)T`Z@D$
MZ+_NX(I">[.?XWM7MCN!N)F4Z-48MA>'Y%D5U8SG6F([$.KJI4AQ"E.K2GSI
M*T):91KJZZM*$ZJ4!P10E/1#[?,^WO[[<7WQHJ2=7;8;,7649[EV5/17F(#=
MKD%?=0L<PR+*4/)>NYS]MUO14**F(C*U.!.J`HBES=__`''/=J':#O=OA6J:
M&38UBBZW"FW@2AS-,HDL8]C2R@`^:(5E8(DE&GQI9(]O!%%\_I_^WV-OEW8;
MC=Q.Y'7E#^R51'OZZ=<%4]ZRW9W*E624Y#,7(6LN3ZFLA3I"-2>F1)2L'5`T
M(II/N]_/J5J?B.O(D>`T'A[N"(<$7$;D[=8;N[@66[8[B443)\%SJBGXUE>/
MSER&XMM2V;"F)D1QV(['E,J6A6J'&W$.-K`4E0('!%[^/4-9BU!1XQ2QS$I<
M<J*ZAIHA>?D&)4U$1J!6Q3(E.ORI!C0V$(ZW%K6OIU423P1>NI10.I/B/`D@
M)'TJ)Y!.GO\`;P1,I9TJ)WL>K#B>U3K3-[L7Z>N$R]P<]C.H$FFONX3<Z']T
MXM2S4_%&DR,7QU;CRFG$DH=;=3RUYD4?_;6RF^E7ZPLO'K"1)K-N:O<R1A-P
MJ6I8C3]B=XG(\C'[J2`$I>10,V<%_JYA#M6KWJX(IU;92I.J#U(5\:5I(6VX
M'`'0ZVL<EI<2L'4:CW<$6RQ]L_LG\XX(FJ.^&0AG>_#O-82^G\`0#HX'P@:Y
M'?!0+C+B"#H/R<>-/Q!+BTB^\!@F7$)E/[MQ'0EII[[=Z<0(/SK8OI/'(_E&
MZ+'AI]]=V#_E1KH=H9<>R##$'!*NZ="?-6XF1=AA"$ZM^=/EJG*@,<AH2M0.
MG+3V<=\Z*RV$T=M[I@8[F44(,TSPVH%=7E]6T(T\M%@N9A?VY?)X[6MH1[+#
MOII4'O6+N`D2\3W'Q/)7HT=G'+3&J^CC?=DM,NIJ;JH>E.RZ=<Q!(966IC;S
M:3_B:$<]-.+WWD+S-\B]3,7SOD&EW*M]8LBXHWNN8;*?A8"TEY=2I:[45`KH
MK?)S??L1/B&CBO6DN)]DD=_8::HSL9WABQ*E#*)+(0MM#0*7@2-4!/42"$DI
M/,_W<2?RAUEM;+`LP[9X',%7&5KAZ]=F>KZQ&NY'8L;?<L3@>+="C3KOLC'I
M7G[K#I4]['JR]?L[*3/KZNUL!#?5!"4,(G0FDK;<=;EK:4I/@=`/'7B5<+<Y
M?(\BR7F2M+2YD?(]PA,TD?"P@<)8WU6DNUXJ:Z"O8NMF.*.Z;'%-X8&YX017
MN.AI^=(?W=LH+:Y;+F*5M5+;2I):^8MTR622H*#B)-@I:=/>$GE[.///KGE<
M;$R6V?A39SO:YO%XCR*G0$>L0:>52URU"\>&?>@X<0TX&BODJ`E6]BCR7MH+
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MIP1))[B^XONBJ.[6I[?/59S+/-T=EL%SFM<W,VWPRQ<V_P`*RK$)CBC3;ATL
M?#*RB7DU&S'4B>S'>4''$,OQ26W_`(N"*:_L5AFRF#[4853]O5!B&.[0R*:%
M=X5&P9B.Q03JJYC-S8UO'?CE2[)VR8>"UR'ENO.%1ZU$\$38GKVU-K9^G)GT
MFL"RW0[A[7WENE"BD?=#&1HA/+61^@W*GLJ.O($:^P<$2#_Z9^[J?PEW<8R%
M-"_;RW:W(%-E"0X:F339-6-K2O3J4VQ+8<;T\-3KXJYD4HG@B'!$/[?]FOYA
MP1#@B(;NAWYQKMA[?=V-^LL6C[IVUP^TOF8:UI;5<W?E&'CE`P5J2%2+N_E1
MHR!SYN:Z:#@B8M],O,>\/879#(LXG>GQN_O-GO<_G=QW`YKNS!W8V<Q1G+$9
MLD3,73"I<IR-O(H%=`HGTJ91*2EP&0I6@"@`1-Y^M]CV^6[=UMMW+Y_V<[A=
MMD&!6(VGRO),ESK;?,X>22GY,VZPYM"L&M9TJNL(/F3V6W9"$H>0$(2=4IX(
MI&WI.]S:NZ;L@VCRZVGB;G6#5_\`*?<7K4#*_$^"LQZ]BQE`GS2YD&/+A3RI
M7-2I"O:#P1.3L?;/[)_..")I'O\`)*X6\N&R`@*3_+V.0E>H2YY>1786$G30
MJ3YB=1]/'C)\18RQ=:,-<PL-6<N1U?V-'OEWN5L9TCCADY9N62%W$;T[?JX_
M*BZVWS>78I8@OW"X-=$6AU_J>6U7Q6PK12FHK'0V](6.24E)"U$!1`)/$9='
MN?[R]A9B[FY>W&$@//$6@M&K@P@UXJ`TT%3VC=9WF+#V\3?5;XDKAI7V0?Y1
MW'H!U2SL?RW#\HJ[#';>IA2=N:6J?F6T.WCL296027'41X,F2KH)CS9D]T!M
M#2TEH>!('+?'DWFODSFVPGY3OK!DG(5A"\NCGX9/>7FM'N+N+UJG34T[U$=Y
M99/'3^^6CO#OGN(JTD`-IJ!H.P:U&J\^DPO8W'CAU^K$$-MVTNP#[,RZM;.N
MJ%P9K<>/(CPIDTL+9;>6G5"TD!(/CISQG+?(O0GE6;#\R18;A^TY'Q"(2&2-
MA93UBUU`/(`"N,V2YER'%82/:6,8*&M"6T%*FFY&_=WK0S_.X5@)6-WCL*!<
M43\B+4WT=EMB.IE+I;8KI\=L(0W%=0I)9D-:>65)'2!SX^;GSJ5AG,EY8OG,
MMKFS<_W.6,\'J/H"'\(!=P\+:5K2IINKV'P+WO-P6\;7$5!W!&M?Q$)"FX^<
M6,KS:V?,5)3'_=(3+_BRQY"B-&7W_-?21TZ@I<()Y\><74CJ%ELEE'8K(S^]
MPAU`]YT:.]IU)([*T4T8##,#&\$;!("*>?LIHG#.P<+.RM@\O_SLYO%)/L(3
M$K$*YZ`$I6-#](X]/_AZO\'H7</D!$;\U/("1H6F.!ORU8?)2FJA/JY`X\SQ
MQ@M+F1"ORE+<*@!U$Z`**>KE]H#JTTUUU`_)QO='7A%=/SJ,SNH^'J+Y&GO0
M[_NTWTX,=F?.81AF10]_NY-,%X.(1!QU@VM/C=DE"EM=?W"TOJ#@(0[:L_I)
M`'-44@N.VPPQ'9C--LQF6FVHS+2$MM-1FTA##32$`(2TTRE*4@<M!P1(9]2G
MMQ;[I>S#>G;"-$;F91&QYW.L""D]#C><X.I>0TJ6'4I<+2[-J*[`5R/[N20/
M'@BCS?TZ?<X,3W4W2[5LGG*AU^Y]4C<;`(5@X6_*SO$V!7Y73P6WE(TE7&-*
M3(4T`5*5`4`-0>"*8&G3IU!!Z1S\?9XZ'30Z'E[M>")G+UXEI_\`S>W*!4E)
M<SO:E*>LA(U_&D!1ZB3H-$H)/T#@B1S_`$U*M-C>YM0.FN\>+A/@3K^"?:GG
MTD:ZD'3EP1*B]:OT_P!'=CL9_-W;FD0]OSL;6S[:L:A,H7/SW;YL*FY)A:T)
M`=DV$!*56%4G4D2&ELCD^>")M_T%/41_#]G![&]Y+QUJGN94N5V[WEH\LMU=
MRZ9$JXVGG2I2E*839K0N;3M*5JT^EV*`.MI/!%)QW]V;Q;N*V3W0V0S!.N.;
MEX=;XO8/>7UN5SLYA2JRV;:5T%;]39LLRFTZ@%;("N"*%%V3[JYWZ1'J'7&#
M=PU?-H,3LD.[8[LRBQ)$.;A-G:*F8?NY1=+;C=G0P9S#,WK925?)OR4<EMJ1
MP13JZ6ZILDJ:N^Q^UK[JDNX$2UIK>LE-3:VUK)["9,&PKYL=3D>7#F1EI6VX
MA2DJ2H<^"+TSRUUU&FNNH(/+QY$`\$1-[];Z;;]N.TN9[S[K7C-#A6$5,FQG
M/N.M)DV<Y+2TUV/T[77YDV\N)90Q&91S6XOGHE*B"(C_`$^M\-T>Y/M6P#?K
M=R#35%]NM89CEN/45+#$!BCV^EY;;1<"JI1,B09MBUCL5E;THE/S"E]8`!`X
M(FP_5:R29W7]TW:3Z8V&V+CE=E^:U.\G<4J$YYB*[`<=3+L*NHL"@_N5O4E=
M/G^4LZE3D593S!X(I`576U]-7PJFI88B5=9$BP*V'&0EN/#@0XS4:%%8;0`E
MMF/%:0A*0.03P1)1[[^W2%W4=I.^&R;\9#]KDF'3++#'EI\QZ#G>,I3?8C)8
M.FJ7#=5S32E>*FGEH/(\$48+^GL[DWMJ^Y+/^V/+Y'W16;VU*YU'!EJ=8C5^
M[6W8DM/5[7S!Z1,O,:<ELJ2/B>>KVTZ:Z<$4SR*M*E<M?\,*&OQ<B0!JL$I*
MN7,:Z\$2/^\'8*RW@QZLN\40V[FF(H?7!@..M1T7M7(4')54E]P#R9B7VDN,
M$GH)ZDG[0/&E'WS?N^9'K/RG%D.4:?OI8@4;VS0-=Q^%IK3B+^_?92)T^YL'
M+E_X=W7[,D=5W<'4I7Y*53."G[S$Y[M5>0[*DF19(1(@6<=Z!)CNI!2I/E2F
M6%.)4E)(*>L>T'3CQ/O\;S'R;FIL7D@^UR40X)(`'`1N&E=AOYANMC99+?)P
M^]65'6DH!W'X;HU*?=QZ'5IK&I2='9+<R8XIT(*C%"TQ`KG\26DNJ5IX=1UX
MDO$]8<UA<3%C6E[65_XAUJ6^58F3EV*X-32JZJPWD1(I*>)\W%+<)5H#J[X(
MD24/DZ]7ZR1^3CN-UUTO+C#8TPN?X%I<W#F;[<0HOEM^581D'`@?5_DV1?Y3
MN<]>)8=>FI7+3#9CO+\Q+BW"PT&V)2M?%;C!2#KXD:Z<1?S9U*S',LXN8'</
MB1@ESJU%>[YZK)V'+\D#8Q;@%I<[B]%/SKP\(P+/-V;V'28C56-R^LM)<F*C
MO_=50TIP)5(L;!Q+<1AIM*NK0N*6O0A*2>7%OISTIYZZO908SEZRFO.-X8^:
MCJ1-<:%YT.C1KN-EDLOS#B>5HQ-=$"5FH&FI&M*)]W:#;>OVFV^Q_!H#XE?=
M49;DZ84!HS[:6ZN38S2@::>:^Z0G771"0/9Q^@'I'TXQW2GIU9<F0@>[V[`Z
M9P&\KJ%WT!:A9W,3<P9R?-/^K>Z@'=^%44'<MC_>%E,6DJ^U3<O8W:YM^+:,
MY;DNZF"Y3G.0Q9+RXS=4YB4"IMJVA;2VTIXNF<ETJ7T=(*0KB7S32FU!3S4T
M6'='X9X/PUU3,^S?H]=\6PO<#8]TN"=[NVF3;VY`O(59C=;B[59+=5^:-Y1Y
M3E[#OV49$7U0I+L9E3?RQ8^5+2/*Z0GI-%1/\;01=W8>WU''WTM<`NMST&=^
M(K/;"LOJ?"Y6LU_[O755N23)UM'4FO\`*2[UN%*G`2G0'@B(KN:Q;O>RN7%K
M>UK=38/:S&I&./Q;ZYW.P'+\TS.-D+TAY*9^-BINJ_'V(+-<XV4)DM.NA])5
MIT\B11_<:_IV.X#%<HJ]Q<9[T\4QS<*BNQD]+E-'@.2QK"LOS*7/5:Q9K>1L
MN-ONRGG>K1'0I#BD%/22.")^3MPPKOYPR'?4O<?O/V];O18^*2H^$9-B.W.6
MX?EKN9LJ\NNGYQ'3:.T-A3+C`&4(;#$EQS4I(\>")OONP]/3U(>]W&(.!;X]
MW?;WC&W$.WB9"K!]JMG<SAU\^\@!S[MEW4^[R*3<6Z:Q3A6PTMUMD.?&6R>"
M(NNT_P!)_OR[&+3);7MR[S-F$U69?=JLPP_/MH,FM<5O9%0EQJOGKB1LB^\:
M^SB,/J:3(COH5Y1Z5!0X(GZ]KVMRX^!8PSO%8X7;;FL5_1F%CMU!M:W"9=KY
MRU>;C]??2IMS%B?+>7JF0XI?F=6GPD<$4>'NJ]`BTW6[E\IWD[?MZL1V2P[*
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M)M%7;EY72X60L.09!M%EW]T@!/V3\)*21/V]I^`]^>`6'W+W2[Y;';VX9#QN
M1%J[_#MN\DPO<N5?MS*U%=*R&2]9.XS.@"K;D^>MN,U(=D+;5KH%$D2WW].L
M:_JC^_[1XYL#^*HIP)JN<M\9QV_\O[^Q^FN_+)*/O:KA6?E^.GDF<RZI!]_'
M7LORERYF>)V5M;>XB/M-D:TM=W<6G8:$:]@5^*>>%P="\M<-C4BGSKPOY9[<
M?\OL._W5H_\`0^.N_P"F'3?_``7%?T;?R+Z_M/*?WD_SW?I(?RSVX_Y?8=_N
MK1_Z%Q7_`$QZ;_X+BOZ-OY$^T\I_>3_/=^D@-L]N`I*OP#B"".8*<9HFSKRT
M_P#8JUTXH.F'3\/$EMA,:7M.[6-%/F7)N8RK`0)WNKW/=I_O=JZV!75U7&3#
MK(,&NBME);BP8K,-@>_1J*AMK4>SX0->.Y6%E88J+W:RMX[>/:C``/F`6/F=
M>7#O%E<2!WDGZ5O<?<K:H3TA2@DK*4E00G0*7T@D(220.I7@->6IX(B-VVWN
M@;H9QF^+4F+Y!7P\"2F)>W=X(L("^=EJ8131ZUA4ISK#3#KBW"\!H@?!\0/!
M$>?C]/Y?\NHX(BPIMU<<N=S<FVGAPLA;O\3J8EQ.F2ZB0Q1.L3/(T1!M%DID
MO`24`ZZI5H>D_">"(S^"(:\$50-=?H(!\3IU:Z$Z`Z#4>/!%0<^?OX(B9WLW
MGJ=D\;CW]MCN09`FRE"LKV:9J.F.NT?!$6#,G/O(^2>FGDV0VYU:'@B-BLD2
M9=;72YL7Y*9*@Q),J$7?/,.0_';=>BE[RVO-4PM925=*=2/#@BWN"(<$0X(A
MP1#@B'!$."(<$0X(AP19F/M']D_G'!$'_M@_YH_.K@:EA94@'N18?[?Y.*,'
MAMX!J/*J$!PH=D->.5?-\BX>%'W(:\*^;Y$\*/N0XLRPLFIQ]G=INKC`(Z\&
ME4.*LB:SV2:(2XG<H<7$1>;LY["VQVXR[.I:FO\`4-1)=B,.J"1)M7T_+U<;
M4_HR)SS8(T/('@B0/M=N-FFR6T^*Y/#P!O(J[/\`-Z^3G.:W%I\I8W>09?8%
ME*,;J&&S)L(E1%*&C*<4EIYX+#22D=7!$XOD^1MXS6.6!@SK1Y3[<:'7P&=7
MI#[R'5M%]]PI8KXB$M*4](=T:8;05*/@."(I>W[=;(-X<:O,KN,<JL?A(RBP
MI,?E54N791[^KKFT)-DU*E18JWD_-A384E*&UELZ`<$5UGN];7>X\_:W;&IJ
MKFYQV&U/SC)+Z4\SC6'B2G^"J740"J7:WDI8T+390EH<U'D1P1='LUNE%W9P
MI.4(BM5LN'=W&-W,5EY<B(S:T<PPY3L&0ZAI;\!\*0ZA2@%!*]"/;P1)KW,S
M'<'<O?S"]M=N6I]$K;MF7F^3"_FV-#47"FUH:JXULBCD2+)VK?7Y9::6@%X+
MZND((/!$>>P.\DW=^IRA-Y21,?R?"LJFXG?Q*Z8Y.J7Y47S`W-K)3[;+RV)"
MVE)Z%)U1IKKSTX(B#[C<FBY+OQLQMB8\JYB8NZ[N'<X[6-AV=D%NE!_#-(RV
MY_#@E4?SG''%H:884MQ9T`U(CAV]WESF[WGR/:+/,-H*&768M&RR#/QRZDW+
M#<64[&0F%8/2(D5M<G20?B;2$DH.@TX(CGRW-:3#8L1RR5)E65K,%;18_6,&
M9>7UFI!=1`K(25!3J_)2IQQQ72RRVDJ6H#Q(B2JMX]P[O>Z#M2C#,>J8550?
MBC.;`W<B^E55?.0XW2UB'H<>'7Q+J5*0"M*B^@-D$:CGP1>GW`;VVVSV*S[N
MGQ9FYE06J^0](NICM31LILIJ(,.O;E):4Y9WLASS%B,T4I;8:4ZXM*?$BU\.
MW2W<S/(<-E0MK(43:[(ZLOS\ME7B4VD.6BN\\SHM2LM.N4LRQ_<PRI)<D-#S
M3TA2>"+%W";]6&S6.2K*GQR/<V$:15L..WLIVII4N6SZT0XD5Y"''+6Q<BM.
M2%M-%*8S#96ZI)*4DB+_`"3NGR?',BVH8E[?1V\>W*::<9B?/3).>/,*2RR;
M.OQAF,GR8$J<^$PTO++LAL%2PT/`KS(VN;5=_MMO/G&8;Q9MMK?852U%;B=#
M`MI%G4W;]O)J9UFII<*AO'C&8@*M78SBE.(8*@RMM2=5#GP1[&M;Q`E'=EF7
MTV&U[4^X>=*IDIFNJ:R$RJ7<7MM("_EJFG@-GS9<U_IUT`"4)!4HA()!640[
MV\^XDG>?#=IXF$4-4;*HD9AETF9>/75AC^),+7'9;D-0&(<.'=3)20E(ZY#:
M0L>.FI(E/`DZGI4$DI*"H`=2%(2>6A.NBB0>0_NX(MAC[9_9/YQP1!_[8_9'
MYSP18>"(<$0X(AP1#@B'!$C/NZ9EV\C9['+.HR"PVUEYPBTW#D8]3V-V^(M4
MEE=9728E9&E251YCCCG5H@CX?8=."+N(N)VN[.5XCD>0T#^*[8;=.-6.$X9:
M14Q+7(<DCL?+5V2WE2A2TT=32Q]17PW2I]2]7%I0`$DBT>ZZXS")MVQB^%U>
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MU!<BUZ%>6DD:J/4H:ZC@B(#`YLK#LJSW?[<+`<\F7VX>?O85BM73XU-L[K&<
M)KNIABQ?K1I)8A3_`)8=+B4=:DCX00K@B/G:S;^QCY=GV[^6Q%UV5;B28<:N
MJCY2GL9PJI2TQ1U<HA2PU;RDI5(FI25)2M?2#J-."(E6,LSQ>_&\]LO;?*KR
MYQ:H8QO;&=*@*8P^FH(\1ZQN;9RQ>*$RK*[L&FE^7$2](?0A+0Z1KP1;?9]4
M9JFKR',LNH+:-D6X%O-N\NO\GAO5=M8SVGTLT=/1USW\2*6MA!YQUUX)0%N(
M;:Z@E2@1>WOKA5SO!NOM=MK)J;3^6=&9NX.<7(COHIK%<9X1JK&S+"0R]*E(
M:(+:25!#JB?#@B5ZREIIIMMI"666$)9;:0A+:66FDAM+24))0E+:$!(`Y:`<
M$2/,MPBVWL[@(,7*J6R:VDV6BL6K`L:UYBOSG.;$"2V8*%#R[*OJF&FT+4G4
M*4V4#[9X(N6QVLRB==;M=U.8X7=NWM!!NJ;9[`YU>\;&OIJ5IR+%LDUG27F[
M"WE+Y*"=0VMT@?95P5YKVAO"=NU=[VGXWD='ADJ\R:BE0;C-)+F6Y7<7L=VN
MR*ZRRS<?=?8;K%_O(>/TL%:(T93_`$/.N!:@A+9`X)*]KAH5S<[(\V<[DLX?
M<V\R/)'\0Q6!3;4/JB.,8?6&TBB=DV26EN[TM,RIZ4AI'DAU]UMI3+82M6I*
MRO)[1:_.;"XS?<;-,=M&<FSB[L3DV19)7O4JF:RHZ(N.X_B=<^E$J1&<<ZGI
M#A2F.TVVA">IPD@B7;P19F/MG]D_G'!%>ZVI2@1IIIIX_2>"+'Y*_H^O@B'D
MK^CZ^"(>2OZ/KX(AY*_H^O@B'DK^CZ^"(>2OZ/KX(JAIP'5)(/+]+EXZZ`>`
M!]O!%;Y#FJCK]HE1!5J-3[1KJ1^;@BM,995U=1&H`Y%/Z*NI//IZ@`?9KSX(
MLH;<`(T1H1H0=""3XJ5KJ5$_2>"+&8RB.DE7EZ:%M+B@D_$%$<R2!J!R!'+@
MB(CN$H]U,MP*]PC;*GJS+R>O-=.O[7(6ZI%;!?4?GHT:*W"E/OR)3"?*Z]4)
M0E9//33@B[W;+&7\6P#$L8=J$41H**'3+K&[!JQ;08L9IEYY,N.AIIXRGD*<
MZBD'51)`)/!%W?DN:::C7WZZZ^_77W\$5/(>Y'S%A6A!(<5H2?$]))2/H&F@
M]G!%<&5C0#V:>)!)T]^HYZ\$5?*<\=22"=.I1(`U)&@\.H`Z`^(X(K2RZ23U
M:ZA*5=1UU"3KJ--"%:<M>"*GD+T(3TI3U`A*>24@(Z`-!R)"OBU]_!%4,N#V
ME7/D5*U5I[!U>)T'+4\^"*X-.Z`+(7IIIKR&J5%25%(Y%0]_O'!$"TX?:?$:
M:+((TZN74-%'4J]_LX(K0PM))'CKJ"5=6A(T)/5KU+4/$^T<$52TZ=1U:(^$
M!*3]D)'())UTY\]=->"(>2YXDA1]JB=5>SD#XI1RUZ?#7GP1#R5_1]?!%D:;
- -4E1)TTTT\?I'!%__V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
